TSE:FRX

Fennec Pharmaceuticals Competitors

C$7.54
-0.54 (-6.68 %)
(As of 04/20/2021 11:19 AM ET)
Add
Compare
Today's Range
C$7.54
Now: C$7.54
C$7.61
50-Day Range
C$7.51
MA: C$8.59
C$9.79
52-Week Range
C$6.29
Now: C$7.54
C$14.08
Volume308 shs
Average Volume1,531 shs
Market CapitalizationC$196.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Fennec Pharmaceuticals (TSE:FRX) Vs. APS, BU, BLU, TH, NRI, and PLI

Should you be buying FRX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Fennec Pharmaceuticals, including Aptose Biosciences (APS), Burcon NutraScience (BU), BELLUS Health (BLU), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), and ProMetic Life Sciences (PLI).

Fennec Pharmaceuticals (TSE:FRX) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Analyst Ratings

This is a summary of current ratings for Fennec Pharmaceuticals and Aptose Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00203.00
Aptose Biosciences00203.00

Aptose Biosciences has a consensus price target of C$12.00, suggesting a potential upside of 92.00%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Fennec Pharmaceuticals.

Earnings & Valuation

This table compares Fennec Pharmaceuticals and Aptose Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$170,000.001,153.31C$-24,858,868.00C($0.96)-7.89
Aptose BiosciencesN/AN/AN/AC($0.84)-7.19

Aptose Biosciences has lower revenue, but higher earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fennec Pharmaceuticals and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/AN/AN/A
Aptose BiosciencesN/AN/AN/A

Summary

Aptose Biosciences beats Fennec Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

Fennec Pharmaceuticals (TSE:FRX) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Fennec Pharmaceuticals and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Earnings and Valuation

This table compares Fennec Pharmaceuticals and Burcon NutraScience's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$170,000.001,153.31C$-24,858,868.00C($0.96)-7.89
Burcon NutraScienceC$12,045.0044,725.45C$107,101.00C$0.005,030.00

Burcon NutraScience has lower revenue, but higher earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Fennec Pharmaceuticals and Burcon NutraScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00203.00
Burcon NutraScience00103.00

Burcon NutraScience has a consensus target price of C$5.00, suggesting a potential downside of 1.77%. Given Burcon NutraScience's higher probable upside, analysts plainly believe Burcon NutraScience is more favorable than Fennec Pharmaceuticals.

Summary

Burcon NutraScience beats Fennec Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Fennec Pharmaceuticals (TSE:FRX) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Fennec Pharmaceuticals and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/AN/AN/A
BELLUS HealthN/AN/AN/A

Valuation and Earnings

This table compares Fennec Pharmaceuticals and BELLUS Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$170,000.001,153.31C$-24,858,868.00C($0.96)-7.89
BELLUS HealthC$15,000.0027,940.20C$-52,720,801.00C($0.67)-7.95

Fennec Pharmaceuticals has higher revenue and earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Fennec Pharmaceuticals and BELLUS Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00203.00
BELLUS Health01202.67

Summary

Fennec Pharmaceuticals beats BELLUS Health on 4 of the 6 factors compared between the two stocks.

Theratechnologies (TSE:TH) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Valuation and Earnings

This table compares Theratechnologies and Fennec Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$65.76 million6.29C$-35,948,380.00C($0.38)-11.50
Fennec PharmaceuticalsC$170,000.001,153.31C$-24,858,868.00C($0.96)-7.89

Fennec Pharmaceuticals has lower revenue, but higher earnings than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
Fennec PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Theratechnologies and Fennec Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
Fennec Pharmaceuticals00203.00

Theratechnologies presently has a consensus price target of C$3.75, suggesting a potential downside of 14.38%. Given Theratechnologies' higher probable upside, equities analysts plainly believe Theratechnologies is more favorable than Fennec Pharmaceuticals.

Summary

Fennec Pharmaceuticals beats Theratechnologies on 5 of the 8 factors compared between the two stocks.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
Fennec PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and Fennec Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
Fennec Pharmaceuticals00203.00

Valuation & Earnings

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Fennec Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.29C$-6,980,844.00C($0.61)-57.68
Fennec PharmaceuticalsC$170,000.001,153.31C$-24,858,868.00C($0.96)-7.89

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than Fennec Pharmaceuticals. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Fennec Pharmaceuticals (TSE:FRX) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.

Valuation & Earnings

This table compares Fennec Pharmaceuticals and ProMetic Life Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$170,000.001,153.31C$-24,858,868.00C($0.96)-7.89
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A

Fennec Pharmaceuticals has higher earnings, but lower revenue than ProMetic Life Sciences. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fennec Pharmaceuticals and ProMetic Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/AN/AN/A
ProMetic Life SciencesN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Fennec Pharmaceuticals and ProMetic Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00203.00
ProMetic Life Sciences0000N/A

Summary

Fennec Pharmaceuticals beats ProMetic Life Sciences on 3 of the 5 factors compared between the two stocks.


Fennec Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
APS
Aptose Biosciences
1.3$6.07-4.9%C$566.20 millionN/A-7.19
BU
Burcon NutraScience
1.2$5.03-0.8%C$543.00 millionC$12,045.005,030.00
BLU
BELLUS Health
0.5$5.35-8.2%C$453.57 millionC$15,000.00-7.95
Theratechnologies logo
TH
Theratechnologies
0.7$4.37-2.7%C$424.76 millionC$65.76 million-11.50Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.36-0.3%C$402.68 millionC$76.09 million-57.68
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
NEPT
Neptune Wellness Solutions
1.2$1.52-4.6%C$263.13 millionC$52.78 million-1.13Gap Up
MDNA
Medicenna Therapeutics
0.5$4.79-1.3%C$256.58 millionN/A-15.50
EMC
Emblem
0.5$1.88-1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.34-0.0%C$226.16 millionC$3,000.00-5.78
RVX
Resverlogix
0.7$0.89-2.2%C$212.93 millionN/A63.57Upcoming Earnings
News Coverage
ATE
Antibe Therapeutics
1.3$4.32-5.1%C$206.60 millionC$9.33 million-5.49Gap Down
ONC
Oncolytics Biotech
1.2$3.61-0.3%C$191.02 millionN/A-6.45
IPA
ImmunoPrecise Antibodies
0.4$11.29-8.1%C$123.03 millionC$17.18 million-52.76
HBP
Helix BioPharma
0.5$0.88-2.3%C$119.96 millionN/A-16.00Gap Up
ACST
Acasti Pharma
0.8$0.54-1.9%C$88.79 millionC$81,000.0015.88News Coverage
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.59-3.4%C$66.76 millionC$11.64 million-11.57News Coverage
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.33-4.5%C$58.80 millionC$123,870.00-25.38
PMN
ProMIS Neurosciences
0.5$0.19-2.7%C$55.07 millionC$1,787.00-9.25News Coverage
Gap Up
COV
Covalon Technologies
0.6$1.55-3.2%C$37.44 millionC$23.84 million-6.51Gap Down
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25-2.0%C$34.02 millionC$13.02 million-0.36Gap Up
IGX
IntelGenx Technologies
0.9$0.55-1.8%C$30.87 millionC$1.54 million-6.79
QPT
Quest PharmaTech
0.8$0.11-13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74-1.4%C$21.65 millionC$16.14 million22.42
CTX
Crescita Therapeutics
0.6$0.80-6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.20-2.6%C$14.12 millionC$1.34 million-5.57
GSD
Devonian Health Group
0.5$0.26-3.8%C$13.96 millionC$1.59 million-5.42High Trading Volume
PAS
Pascal Biosciences
0.6$0.08-0.0%C$12.70 millionN/A-3.64
NSP
Naturally Splendid Enterprises
0.6$0.06-0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63-1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.34-1.5%C$10.16 millionC$4.12 million30.45Gap Down
HEM
Hemostemix
0.6$0.33-6.2%C$9.07 millionN/A-1.93Gap Down
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38-2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17-5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.65-4.7%C$4.48 millionN/A-1.18
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.65-2.0%C$0.00C$267.59 million51.26
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.